Literature DB >> 33597002

Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects?

Grazia Daniela Femminella1, Nicholas R Livingston1, Sanara Raza1, Thalia van der Doef1, Eleni Frangou2, Sharon Love2, Gail Busza1, Valeria Calsolaro1, Stefan Carver1, Clive Holmes3, Craig W Ritchie4, Robert M Lawrence5, Brady McFarlane6, George Tadros7, Basil H Ridha8, Carol Bannister9, Zuzana Walker10, Hilary Archer11, Elizabeth Coulthard11, Ben Underwood12, Aparna Prasanna13, Paul Koranteng14, Salman Karim15, Kehinde Junaid16, Bernadette McGuinness17, Anthony Peter Passmore17, Ramin Nilforooshan18, Ajayverma Macharouthu19, Andrew Donaldson20, Simon Thacker21, Gregor Russell22, Naghma Malik23, Vandana Mate24, Lucy Knight25, Sajeev Kshemendran26, Tricia Tan1, Christian Holscher27, John Harrison28, David J Brooks29, Clive Ballard30, Paul Edison31.   

Abstract

BACKGROUND: Type 2 diabetes is a risk factor for Alzheimer's disease (AD), and AD brain shows impaired insulin signalling. The role of peripheral insulin resistance on AD aetiopathogenesis in non-diabetic patients is still debated. Here we evaluated the influence of insulin resistance on brain glucose metabolism, grey matter volume and white matter lesions (WMLs) in non-diabetic AD subjects.
METHODS: In total, 130 non-diabetic AD subjects underwent MRI and [18F]FDG PET scans with arterial cannula insertion for radioactivity measurement. T1 Volumetric and FLAIR sequences were acquired on a 3-T MRI scanner. These subjects also had measurement of glucose and insulin levels after a 4-h fast on the same day of the scan. Insulin resistance was calculated by the updated homeostatic model assessment (HOMA2). For [18F]FDG analysis, cerebral glucose metabolic rate (rCMRGlc) parametric images were generated using spectral analysis with arterial plasma input function.
RESULTS: In this non-diabetic AD population, HOMA2 was negatively associated with hippocampal rCMRGlc, along with total grey matter volumes. No significant correlation was observed between HOMA2, hippocampal volume and WMLs.
CONCLUSIONS: In non-diabetic AD, peripheral insulin resistance is independently associated with reduced hippocampal glucose metabolism and with lower grey matter volume, suggesting that peripheral insulin resistance might influence AD pathology by its action on cerebral glucose metabolism and on neurodegeneration.

Entities:  

Keywords:  Alzheimer’s disease; Insulin resistance; Magnetic resonance imaging; Positron emission tomography imaging

Mesh:

Substances:

Year:  2021        PMID: 33597002      PMCID: PMC7890851          DOI: 10.1186/s13195-021-00784-w

Source DB:  PubMed          Journal:  Alzheimers Res Ther            Impact factor:   6.982


  61 in total

1.  Insulin Resistance is Associated with Higher Cerebrospinal Fluid Tau Levels in Asymptomatic APOEɛ4 Carriers.

Authors:  Erika J Starks; J Patrick O'Grady; Siobhan M Hoscheidt; Annie M Racine; Cynthia M Carlsson; Henrik Zetterberg; Kaj Blennow; Ozioma C Okonkwo; Luigi Puglielli; Sanjay Asthana; N Maritza Dowling; Carey E Gleason; Rozalyn M Anderson; Nancy J Davenport-Sis; LeAnn M DeRungs; Mark A Sager; Sterling C Johnson; Barbara B Bendlin
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

2.  Prospective analysis of the insulin-resistance syndrome (syndrome X).

Authors:  S M Haffner; R A Valdez; H P Hazuda; B D Mitchell; P A Morales; M P Stern
Journal:  Diabetes       Date:  1992-06       Impact factor: 9.461

3.  Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.

Authors:  Tali Cukierman-Yaffe; Hertzel C Gerstein; Helen M Colhoun; Rafael Diaz; Luis-Emilio García-Pérez; Mark Lakshmanan; Angelyn Bethel; Denis Xavier; Jeffrey Probstfield; Matthew C Riddle; Lars Rydén; Charles Messan Atisso; Stephanie Hall; Purnima Rao-Melacini; Jan Basile; William C Cushman; Edward Franek; Matyas Keltai; Fernando Lanas; Lawrence A Leiter; Patricio Lopez-Jaramillo; Valdis Pirags; Nana Pogosova; Peter J Raubenheimer; Jonathan E Shaw; Wayne H-H Sheu; Theodora Temelkova-Kurktschiev
Journal:  Lancet Neurol       Date:  2020-07       Impact factor: 44.182

Review 4.  Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches.

Authors:  Derek Kellar; Suzanne Craft
Journal:  Lancet Neurol       Date:  2020-07-27       Impact factor: 44.182

Review 5.  Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums.

Authors:  Steven E Arnold; Zoe Arvanitakis; Shannon L Macauley-Rambach; Aaron M Koenig; Hoau-Yan Wang; Rexford S Ahima; Suzanne Craft; Sam Gandy; Christoph Buettner; Luke E Stoeckel; David M Holtzman; David M Nathan
Journal:  Nat Rev Neurol       Date:  2018-01-29       Impact factor: 42.937

Review 6.  Glucose metabolism and insulin receptor signal transduction in Alzheimer disease.

Authors:  Siegfried Hoyer
Journal:  Eur J Pharmacol       Date:  2004-04-19       Impact factor: 4.432

7.  Intranasal insulin improves cognition and modulates beta-amyloid in early AD.

Authors:  M A Reger; G S Watson; P S Green; C W Wilkinson; L D Baker; B Cholerton; M A Fishel; S R Plymate; J C S Breitner; W DeGroodt; P Mehta; S Craft
Journal:  Neurology       Date:  2007-10-17       Impact factor: 9.910

8.  Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults.

Authors:  Siobhan M Hoscheidt; Erika J Starks; Jennifer M Oh; Henrik Zetterberg; Kaj Blennow; Rachel A Krause; Carey E Gleason; Luigi Puglielli; Craig S Atwood; Cynthia M Carlsson; Sanjay Asthana; Sterling C Johnson; Barbara B Bendlin
Journal:  J Alzheimers Dis       Date:  2016-04-12       Impact factor: 4.472

9.  The A4 study: stopping AD before symptoms begin?

Authors:  Reisa A Sperling; Dorene M Rentz; Keith A Johnson; Jason Karlawish; Michael Donohue; David P Salmon; Paul Aisen
Journal:  Sci Transl Med       Date:  2014-03-19       Impact factor: 17.956

Review 10.  NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

Authors:  Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling
Journal:  Alzheimers Dement       Date:  2018-04       Impact factor: 21.566

View more
  8 in total

Review 1.  Impaired insulin signalling and allostatic load in Alzheimer disease.

Authors:  Fernanda G De Felice; Rafaella A Gonçalves; Sergio T Ferreira
Journal:  Nat Rev Neurosci       Date:  2022-02-28       Impact factor: 34.870

2.  Association of Plasma Neurofilament Light Chain With Glycaemic Control and Insulin Resistance in Middle-Aged Adults.

Authors:  Rohith N Thota; Pratishtha Chatterjee; Steve Pedrini; Eugene Hone; Jessica J A Ferguson; Manohar L Garg; Ralph N Martins
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-20       Impact factor: 6.055

Review 3.  A Review of miRNAs as Biomarkers and Effect of Dietary Modulation in Obesity Associated Cognitive Decline and Neurodegenerative Disorders.

Authors:  Maddie Perdoncin; Alec Konrad; Joshua R Wyner; Samir Lohana; Sneha S Pillai; Duane G Pereira; Hari Vishal Lakhani; Komal Sodhi
Journal:  Front Mol Neurosci       Date:  2021-10-07       Impact factor: 6.261

Review 4.  Glucagon-Like Peptide 1 Receptor Agonists - Potential Game Changers in the Treatment of Glaucoma?

Authors:  Zaynab Ahmad Mouhammad; Rupali Vohra; Anna Horwitz; Anna-Sophie Thein; Jens Rovelt; Barbara Cvenkel; Pete A Williams; Augusto Azuara-Blanco; Miriam Kolko
Journal:  Front Neurosci       Date:  2022-02-21       Impact factor: 4.677

Review 5.  Obesity and Leptin Resistance in the Regulation of the Type I Interferon Early Response and the Increased Risk for Severe COVID-19.

Authors:  Frits A J Muskiet; Pedro Carrera-Bastos; Leo Pruimboom; Alejandro Lucia; David Furman
Journal:  Nutrients       Date:  2022-03-26       Impact factor: 5.717

Review 6.  Systemic Actions of SGLT2 Inhibition on Chronic mTOR Activation as a Shared Pathogenic Mechanism between Alzheimer's Disease and Diabetes.

Authors:  Gabriela Dumitrita Stanciu; Razvan Nicolae Rusu; Veronica Bild; Leontina Elena Filipiuc; Bogdan-Ionel Tamba; Daniela Carmen Ababei
Journal:  Biomedicines       Date:  2021-05-19

Review 7.  Inflammasome NLRP3 Potentially Links Obesity-Associated Low-Grade Systemic Inflammation and Insulin Resistance with Alzheimer's Disease.

Authors:  Anna Litwiniuk; Wojciech Bik; Małgorzata Kalisz; Agnieszka Baranowska-Bik
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

8.  An introduction to therapeutic approaches to vascular cognitive impairment.

Authors:  Atticus H Hainsworth; Fanny M Elahi; Roderick A Corriveau
Journal:  Cereb Circ Cogn Behav       Date:  2021
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.